Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06215586 · ClinicalTrials.gov registry record · Phase 2
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
A Phase 2 study, sponsored by Cardurion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 303
- Enrollment target
NCT06215586 is a Phase 2 study that has completed, run by Cardurion Pharmaceuticals. The registered enrollment target is 303 participants.
The verdict
NCT06215586, a Phase 2 study, has completed, sponsored by Cardurion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 303 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
Interventions
- DRUG Placebo
- DRUG Tovinontrine (CRD-750
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2024-02-13 |
| Est. Completion | 2025-09-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06215586
The ClinicalTrials.gov registry entry for NCT06215586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardurion Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06215586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06215586 about?
NCT06215586 is a clinical study titled "Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)". The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
What is the current status of trial NCT06215586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2024-02-13. Estimated completion is 2025-09-02.
What interventions are being tested in trial NCT06215586?
The interventions under investigation include: Placebo (DRUG), Tovinontrine (CRD-750 (DRUG).
Who is sponsoring clinical trial NCT06215586?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.